United Therapeutics Corporation
United Therapeutics develops and commercializes products for chronic and life-threatening diseases. Products include Tyvaso DPI, Tyvaso, Remodulin, Orenitram, Adcirca, Unituxin, and Remunity Pump. The company also develops RemoPro, Ralinepag, Aurora-GT, and Nebulized Tyvaso. Licensing agreements include DEKA Research, MannKind Corporation, and Arena Pharmaceuticals. The company was incorporated in 1996 and is headquartered in Maryland.
Overview
Strengths
- Creates economic value: ROIC of 22.0% against a cost of capital (WACC) of 6.7%, a spread of 15.3 percentage points.
- Pricing power: gross margin has held between 88% and 93% over the last 6 years (latest 87.9%).
- Predictable earnings: earnings per share have grown along a steady trend of 26.8% a year.
- Consistent growth: revenue has compounded at 16.5% a year over 5 years, rising every year.
- Shareholder-friendly capital allocation: the share count has shrunk by 1.8% a year over the last three years through buybacks.
- ROIC of 22.0% beats 87% of its 55 Drug Manufacturers - Specialty & Generic peers (median 10.9%).
Weaknesses
- Valued at a premium to its Drug Manufacturers - Specialty & Generic peers: P/FCF 23.9x vs. a median of 16.5x.
- More expensive than its own history: P/FCF 23.9x vs. a historical average of 15.3x.
Key Financial Data